FREE COMMUNICATION 4

 
11:45 - 13:15     CAPITAL SUITE 7/12 
 
Free Communication Session 4
 
Anaemia - novel approaches
 
Chairs: Christopher Pugh, Oxford, UK
             Christopher Winearls, Oxford, UK
 
FO014
IMPACT OF INDIVIDUAL I.V. IRON PREPARATIONS ON DIFFERENTIATION OF MACROPHAGES
AND DENDRITIC CELLS
Lisa H. Fell, Adam M. Zawada, Sarah Seiler, Kathrin Untersteller, Danilo Fliser, Gunnar H. Heine, Saarland Univ Medical Center, Internal Medicine IV, Homburg, GERMANY.

FO015
AKB-6548, A NOVEL HYPOXIA-INDUCIBLE FACTOR PROLYL-HYDROXYLASE INHIBITOR (HIFPHI)
FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT
ON DIALYSIS (ND-CKD)
Pablo E. Pergola1, Bruce Spinowitz2, Volker H. Haase3, Charlotte S. Hartman4, Tasha M. Farmer4, Krishna R. Polu4, Bradley Maroni4, Robert Shalwitz4, 1Renal Associates PA, Nephrology, San Antonio, TX, 22New York Hosp Queens, Nephrology, Flushing, NY, 3Vanderbilt Univ, Nephrology and Hypertension, Nashville, TN, 4Akebia Therapeutics, Inc, Nephrology, Cambridge, MA.

FO016

HEPCIDIN RESPONSE TO IRON THERAPY IN PATIENTS WITH NON-DIALYSIS CKD: AN ANALYSIS
OF THE FIND-CKD TRIAL
Iain C. Macdougall1, Andreas H. Bock2, Fernando Carrera3, Kai-Uwe Eckardt4, Carlo A. Gaillard5,
David B. Van Wyck6, Sukhvinder S. Bansal7, Bernard Roubert8, Jacqueline G. Nolen8, Simon D. Roger9, 1King’s College Hosp, Dept Renal Medicine, London, UK, 2Kantonsspital, Dept Nephrology, Aarau, SWITZERLAND, 3Eurodial, Dept Dialysis, Leiria, PORTUGAL, 4Univ Erlangen-Nuremberg, Dept
Nephrology and Hypertension, Erlangen, GERMANY, 5Univ Medical Centre Groningen, Dept Nephrology, Groningen, NETHERLANDS, 6Davita Healthcare Partners, Clinical Support Services, Denver, CO, 7King’s College Hosp, Inst Pharmaceutical Science, London, UK, 8Vifor Pharma, Ltd., Glattbrugg, SWITZERLAND, 9Renal Research, Gosford, NSW, AUSTRALIA.

FO017

SERUM BIOACTIVE HEPCIDIN-25 , SOLUBLE TRANSFERRIN RECEPTOR AND THEIR RATIO IN
PREDIALYSIS PATIENTS AND THE RESPONSE TO INTRAVENOUS FERRIC CARBOXYMALTOSE
Athina Drakou1, Stamatia Theodorakopoulou1, Ioannis Agrogiannis1, Dimitra Bacharaki1, Spyros Katsoudas1, Aggeliki Margeli2, Ioannis Papassotiriou2, D. V. Vlahakos1, 1Attikon, Dept Nephrology, Athens, GREECE, 2Aghia Sophia Children’s Hosp, Dept Clinical Biochemistry, Athens, GREECE.

FO018

TRIFERIC ADMINISTERED VIA DIALYSATE MAINTAINS IRON BALANCE AND HEMOGLOBIN:
PHASE 3 STUDY RESULTS
Ajay Gupta1, Vivian Lin1, Carrie Guss1, Raymond Pratt2, 1Rockwell Medical, R&D, Wixom, MI, 2Rockwell Medical Inc., R&D, Wixom, MI.

FO019

JTZ-951, AN ORAL NOVEL HIF-PHD INHIBITOR, ELEVATES HEMOGLOBIN IN JAPANESE ANEMIC
PATIENTS WITH CHRONIC KIDNEY DISEASE RECEIVING MAINTENANCE HEMODIALYSIS

Tadao Akizawa1, Koji Hanaki2, Masanobu Arai2, 1Showa Univ, School Medicine, Div Nephrology, Dept Medicine, Tokyo, JAPAN, 2Japan Tobacco Inc., Pharmaceutical Div, Tokyo, JAPAN.

 

back to the timetable